Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549027 | 0.80 | TSHR (0.31) | — | |
| SCHEMBL9727525 | 0.79 | — | — | |
| SCHEMBL3761618 | 0.79 | — | — | |
| SCHEMBL14478192 | 0.77 | — | — | |
| SCHEMBL9371344 | 0.77 | — | — | |
| SCHEMBL22409399 | 0.74 | CYP1A2 (0.34) | — | |
| SCHEMBL1913007 | 0.72 | — | — | |
| SCHEMBL19963481 | 0.72 | FAAH (0.38) | — | |
| SCHEMBL19963543 | 0.72 | FAAH (0.38) | — | |
| SCHEMBL22892190 | 0.72 | CBLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | claimed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | claimed |
| EP-2117531-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB Science (FR) | 2009-11-18 | — | — | EP | claimed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | claimed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | claimed |
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | AB SCIENCE | 2008-06-19 | — | — | US | claimed |
| EP-1904065-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB Science (FR) | 2008-04-02 | — | — | EP | claimed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | claimed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | claimed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | claimed |
| EP-1746990-A1 | USE OF MAST CELLS INHIBITORS FOR TREATING PATIENTS EXPOSED TO CHEMICAL OR BIOLOGICAL WEAPONS | AB Science (FR) | 2007-01-31 | — | — | EP | claimed |
| EP-1742633-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB Science (FR) | 2007-01-17 | — | — | EP | claimed |
| WO-2005115304-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBRODYSPLASIA | AB SCIENCE (FR) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115385-A1 | USE OF C-KIT INHIBITORS FOR TREATING ACNE | AB SCIENCE (FR) | 2005-12-08 | — | — | WO | claimed |
| WO-2005112920-A1 | USE OF MAST CELLS INHIBITORS FOR TREATING PATIENTS EXPOSED TO CHEMICAL OR BIOLOGICAL WEAPONS | AB SCIENCE (FR) | 2005-12-01 | — | — | WO | claimed |
| WO-2005102346-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102326-A2 | USE OF C-KIT INHIBITORS FOR TREATING RENAL DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102455-A1 | USE OF C-KIT INHIBITORS FOR TREATING PLASMODIUM RELATED DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102318-A1 | USE OF C-KIT INHIBITORS FOR TREATING HIV RELATED DISEASES | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102325-A1 | USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | KIT, CPA3, CMA1 | SIGMAR1 2785/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | SIGMAR1 2972/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | SIGMAR1 3394/4885 |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | KIT, FGFR3, AURKC | SIGMAR1 4884/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | SIGMAR1 2358/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | SIGMAR1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.